Clinical Trial Update: Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II clinical trial evaluating MEK162 with panitumumab in metastatic colorectal cancer with mutant or wild-type RAS; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MEK162 (binimetinib)
• Panitumumab (panitumumab)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-18